Robert W. Baird Cuts Certara (NASDAQ:CERT) Price Target to $18.00

Certara (NASDAQ:CERT) had its target price trimmed by Robert W. Baird from $19.00 to $18.00 in a research report report published on Wednesday morning, Benzinga reports. The firm currently has a neutral rating on the stock.

A number of other equities analysts have also recently weighed in on the stock. JMP Securities restated a market perform rating on shares of Certara in a research report on Wednesday, July 10th. UBS Group reduced their price objective on shares of Certara from $20.00 to $16.00 and set a neutral rating for the company in a research report on Wednesday. Barclays reduced their price objective on shares of Certara from $18.00 to $16.00 and set an equal weight rating for the company in a research report on Friday, June 28th. Finally, KeyCorp dropped their target price on shares of Certara from $23.00 to $20.00 and set an overweight rating for the company in a report on Thursday, July 11th. Eight investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Certara presently has an average rating of Hold and a consensus price target of $18.83.

Certara Price Performance

CERT stock traded down $0.56 during mid-day trading on Wednesday, reaching $12.51. 1,559,225 shares of the company’s stock were exchanged, compared to its average volume of 582,396. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.26 and a quick ratio of 3.26. Certara has a 12-month low of $11.81 and a 12-month high of $19.87. The stock’s 50 day moving average is $14.93 and its 200 day moving average is $16.47. The company has a market cap of $2.01 billion, a price-to-earnings ratio of -32.08, a price-to-earnings-growth ratio of 5.39 and a beta of 1.52.

Certara (NASDAQ:CERT) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). The business had revenue of $93.31 million during the quarter, compared to analyst estimates of $96.01 million. Certara had a negative net margin of 17.02% and a positive return on equity of 4.08%. The firm’s revenue for the quarter was up 3.2% on a year-over-year basis. During the same period in the previous year, the business posted $0.10 earnings per share. On average, research analysts expect that Certara will post 0.28 EPS for the current year.

Institutional Investors Weigh In On Certara

A number of hedge funds have recently modified their holdings of the company. Mubadala Investment Co PJSC purchased a new stake in shares of Certara in the fourth quarter valued at about $169,135,000. Wasatch Advisors LP grew its holdings in shares of Certara by 23.4% in the first quarter. Wasatch Advisors LP now owns 4,924,845 shares of the company’s stock valued at $88,056,000 after purchasing an additional 932,598 shares during the period. Geneva Capital Management LLC grew its holdings in shares of Certara by 15.1% in the first quarter. Geneva Capital Management LLC now owns 4,404,199 shares of the company’s stock valued at $78,747,000 after purchasing an additional 579,349 shares during the period. Clearbridge Investments LLC boosted its stake in Certara by 0.8% during the first quarter. Clearbridge Investments LLC now owns 4,173,195 shares of the company’s stock worth $74,617,000 after buying an additional 32,846 shares during the period. Finally, Dimensional Fund Advisors LP boosted its stake in Certara by 9.7% during the second quarter. Dimensional Fund Advisors LP now owns 3,079,023 shares of the company’s stock worth $42,643,000 after buying an additional 273,095 shares during the period. Hedge funds and other institutional investors own 73.96% of the company’s stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.